Predicted protein targets (top 15)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PRSS1 | P07477 | 8/20 | 0.47 |
| ▸ | F2 | P00734 | 2/20 | 0.47 |
| ▸ | PRSS2 | P07478 | 2/20 | 0.47 |
| ▸ | PRSS3 | P35030 | 2/20 | 0.47 |
| ▸ | TMPRSS6 | Q8IU80 | 2/20 | 0.47 |
| ▸ | ST14 | Q9Y5Y6 | 2/20 | 0.47 |
| ▸ | MAPT | P10636 | 3/20 | 0.40 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.40 |
| ▸ | GAA | P10253 | 1/20 | 0.36 |
| ▸ | STK17B | O94768 | 1/20 | 0.36 |
| ▸ | STK17A | Q9UEE5 | 1/20 | 0.36 |
| ▸ | HDAC3 | O15379 | 1/20 | 0.36 |
| ▸ | HDAC1 | Q13547 | 1/20 | 0.36 |
| ▸ | HDAC2 | Q92769 | 1/20 | 0.36 |
| ▸ | NCOR2 | Q9Y618 | 1/20 | 0.36 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL8518743 | 0.83 | MAPT (0.41) | PRSS1F2PRSS2PRSS3TMPRSS6 | |
| SCHEMBL11528091 | 0.82 | MAPT (0.55) | PRSS1F2PRSS2PRSS3TMPRSS6 | |
| SCHEMBL11934926 | 0.82 | APP (0.49) | PRSS1F2PRSS2PRSS3TMPRSS6 | |
| SCHEMBL11934906 | 0.82 | PRSS1 (0.48) | PRSS1F2PRSS2PRSS3TMPRSS6 | |
| SCHEMBL28385928 | 0.82 | APP (0.49) | PRSS1F2PRSS2PRSS3TMPRSS6 | |
| SCHEMBL11748511 | 0.80 | MAPT (0.52) | PRSS1F2PRSS2PRSS3TMPRSS6 | |
| SCHEMBL11935538 | 0.80 | STK17A (0.52) | PRSS1F2PRSS2PRSS3TMPRSS6 | |
| SCHEMBL22082127 | 0.80 | ABL1 (0.51) | PRSS1F2PRSS2PRSS3TMPRSS6 | |
| SCHEMBL4023262 | 0.80 | STK17A (0.52) | PRSS1F2PRSS2PRSS3TMPRSS6 | |
| SCHEMBL11934923 | 0.80 | PRSS1 (0.47) | PRSS1F2PRSS2PRSS3TMPRSS6 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-9150507-B2 | Amine derivative having NPY Y5 receptor antagonistic activity | SHIONOGI & CO., LTD. (JP) | 2015-10-06 | — | — | US | disclosed |
| US-8227618-B2 | Amine-derivatives having NPY Y5 receptor antagonistic activity and the uses thereof | SHIONOGI & CO., LTD. (JP) | 2012-07-24 | — | — | US | disclosed |
| US-20100273841-A1 | AMINE-DERIVATIVES HAVING NPY Y5 RECEPTOR ANTAGONISTIC ACTIVITY AND THE USES THEREOF | SHIONOGI & CO., LTD. (JP) | 2010-10-28 | — | — | US | disclosed |
| US-20100267945-A1 | AMINE DERIVATIVE HAVING NPY Y5 RECEPTOR ANTAGONISTIC ACTIVITY | SHIONOGI & CO., LTD. (JP) | 2010-10-21 | — | — | US | disclosed |
| US-20100063027-A1 | Amine Derivative Having NPY Y5 Receptor Antagonistic Activity | SHIONOGI & CO., LTD. (JP) | 2010-03-11 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100063027-A1 | Amine Derivative Having NPY Y5 Receptor Antagonistic Activity | NPY5R, NPY1R, NPY2R | PRSS1 988/4885F2 3006/4885PRSS2 1471/4885 |
| US-20100267945-A1 | AMINE DERIVATIVE HAVING NPY Y5 RECEPTOR ANTAGONISTIC ACTIVITY | NPY5R, NPY1R, NPY2R | PRSS1 487/4885F2 1417/4885PRSS2 537/4885 |
| US-20100273841-A1 | AMINE-DERIVATIVES HAVING NPY Y5 RECEPTOR ANTAGONISTIC ACTIVITY AND THE USES THEREOF | NPY5R, NPY1R, NPY2R | PRSS1 1193/4885F2 3413/4885PRSS2 1586/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.